Is IRD or MESO more profitable?

Mesoblast has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Mesoblast's return on equity of 0.00% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -1,091.82% -338.88% -150.13% Mesoblast N/A N/A N/A

Does the media favor STOK or IRD?

In the previous week, Opus Genetics had 2 more articles in the media than Stoke Therapeutics. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Stoke Therapeutics. Opus Genetics' average media sentiment score of 1.33 beat Stoke Therapeutics' score of 0.38 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IRD or BHVN more profitable?

Biohaven has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Opus Genetics' return on equity of -338.88% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -1,091.82% -338.88% -150.13% Biohaven N/A -1,328.94% -138.27%

Does the media favor IRD or BHVN?

In the previous week, Biohaven had 1 more articles in the media than Opus Genetics. MarketBeat recorded 4 mentions for Biohaven and 3 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.33 beat Biohaven's score of 0.58 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZYME or IRD more profitable?

Zymeworks has a net margin of -405.31% compared to Opus Genetics' net margin of -1,091.82%. Zymeworks' return on equity of -72.30% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Zymeworks -405.31% -72.30% -37.18% Opus Genetics -1,091.82% -338.88% -150.13%

Does the media prefer ZYME or IRD?

In the previous week, Zymeworks had 1 more articles in the media than Opus Genetics. MarketBeat recorded 4 mentions for Zymeworks and 3 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.33 beat Zymeworks' score of 0.40 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COAG or IRD?

In the previous week, Hemab Therapeutics had 2 more articles in the media than Opus Genetics. MarketBeat recorded 5 mentions for Hemab Therapeutics and 3 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.33 beat Hemab Therapeutics' score of 0.15 indicating that Opus Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opus Genetics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Opus Genetics (IRD) Competitors

$5.18 -0.10 (-1.89%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.24 +0.07 (+1.25%)

As of 09/18/2026 07:53 PM Eastern

Compare

IRD vs. MESO, STOK, BHVN, ZYME, and COAG

Should you buy Opus Genetics stock or one of its competitors? Opus Genetics's main competitors and comparable companies include Mesoblast (MESO), Stoke Therapeutics (STOK), Biohaven (BHVN), Zymeworks (ZYME), and Hemab Therapeutics (COAG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Opus Genetics compare to Mesoblast?

Opus Genetics (NASDAQ:IRD) and Mesoblast (NASDAQ:MESO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Mesoblast has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Mesoblast's return on equity of 0.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Mesoblast	N/A	N/A	N/A

In the previous week, Opus Genetics had 3 more articles in the media than Mesoblast. MarketBeat recorded 3 mentions for Opus Genetics and 0 mentions for Mesoblast. Opus Genetics' average media sentiment score of 1.33 beat Mesoblast's score of 0.00 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Overall Sentiment
Opus Genetics	Positive
Mesoblast	Neutral

Opus Genetics presently has a consensus price target of $11.92, suggesting a potential upside of 130.18%. Mesoblast has a consensus price target of $39.00, suggesting a potential upside of 157.77%. Given Mesoblast's higher possible upside, analysts plainly believe Mesoblast is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Opus Genetics has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market.

Opus Genetics has higher earnings, but lower revenue than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	30.15	-$49.59M	-$1.35	N/A
Mesoblast	$120.25M	16.34	-$57.50M	-$0.28	N/A

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Opus Genetics beats Mesoblast on 9 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to Stoke Therapeutics?

Stoke Therapeutics (NASDAQ:STOK) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

Stoke Therapeutics presently has a consensus price target of $44.25, suggesting a potential upside of 55.65%. Opus Genetics has a consensus price target of $11.92, suggesting a potential upside of 130.18%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

Stoke Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

In the previous week, Opus Genetics had 2 more articles in the media than Stoke Therapeutics. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Stoke Therapeutics. Opus Genetics' average media sentiment score of 1.33 beat Stoke Therapeutics' score of 0.38 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.0% of Opus Genetics shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Stoke Therapeutics has a net margin of -753.60% compared to Opus Genetics' net margin of -1,091.82%. Stoke Therapeutics' return on equity of -59.36% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Stoke Therapeutics has higher revenue and earnings than Opus Genetics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$3.34	N/A
Opus Genetics	$14.20M	30.15	-$49.59M	-$1.35	N/A

Summary

Opus Genetics beats Stoke Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to Biohaven?

Opus Genetics (NASDAQ:IRD) and Biohaven (NYSE:BHVN) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Opus Genetics currently has a consensus price target of $11.92, suggesting a potential upside of 130.18%. Biohaven has a consensus price target of $18.69, suggesting a potential upside of 37.65%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 13.8% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Biohaven had 1 more articles in the media than Opus Genetics. MarketBeat recorded 4 mentions for Biohaven and 3 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.33 beat Biohaven's score of 0.58 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biohaven has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Opus Genetics' return on equity of -338.88% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Biohaven	N/A	-1,328.94%	-138.27%

Opus Genetics has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

Opus Genetics has higher revenue and earnings than Biohaven. Opus Genetics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	30.15	-$49.59M	-$1.35	N/A
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

Summary

Opus Genetics and Biohaven tied by winning 8 of the 16 factors compared between the two stocks.

How does Opus Genetics compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Zymeworks has a net margin of -405.31% compared to Opus Genetics' net margin of -1,091.82%. Zymeworks' return on equity of -72.30% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 33.5% of Zymeworks shares are held by company insiders. Comparatively, 11.7% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Zymeworks had 1 more articles in the media than Opus Genetics. MarketBeat recorded 4 mentions for Zymeworks and 3 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.33 beat Zymeworks' score of 0.40 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks currently has a consensus target price of $41.00, indicating a potential upside of 54.31%. Opus Genetics has a consensus target price of $11.92, indicating a potential upside of 130.18%. Given Opus Genetics' stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

Opus Genetics has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	17.79	-$81.13M	-$2.02	N/A
Opus Genetics	$14.20M	30.15	-$49.59M	-$1.35	N/A

Zymeworks has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Summary

Opus Genetics beats Zymeworks on 9 of the 17 factors compared between the two stocks.

How does Opus Genetics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Opus Genetics (NASDAQ:IRD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Hemab Therapeutics has higher earnings, but lower revenue than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Opus Genetics	$14.20M	30.15	-$49.59M	-$1.35	N/A

In the previous week, Hemab Therapeutics had 2 more articles in the media than Opus Genetics. MarketBeat recorded 5 mentions for Hemab Therapeutics and 3 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 1.33 beat Hemab Therapeutics' score of 0.15 indicating that Opus Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hemab Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Hemab Therapeutics' return on equity of 0.00% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Hemab Therapeutics presently has a consensus target price of $51.40, suggesting a potential upside of 24.79%. Opus Genetics has a consensus target price of $11.92, suggesting a potential upside of 130.18%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

15.0% of Opus Genetics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Opus Genetics beats Hemab Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Opus Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRD vs. The Competition

Export

Metric	Opus Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$428.12M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-3.84	14.23	275.49	25.40
Price / Sales	30.15	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	23.55	15.45	10.46	6.33
Net Income	-$49.59M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-14.24%	-1.21%	0.59%	1.12%
1 Month Performance	25.73%	-3.29%	-1.74%	-2.39%
1 Year Performance	240.79%	37.74%	18.13%	5.35%

Opus Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRD Opus Genetics	3.3986 of 5 stars	$5.18 -1.9%	$11.92 +130.2%	+240.8%	$428.12M	$14.20M	N/A	28
MESO Mesoblast	1.4753 of 5 stars	$14.69 -2.2%	$39.00 +165.4%	-11.1%	$1.95B	$120.25M	N/A	108
STOK Stoke Therapeutics	3.0677 of 5 stars	$28.28 -4.4%	$44.25 +56.4%	+24.1%	$1.91B	$184.42M	N/A	170
BHVN Biohaven	2.9295 of 5 stars	$12.39 -2.0%	$18.69 +50.8%	-5.3%	$1.91B	N/A	N/A	274	Positive News Analyst Forecast
ZYME Zymeworks	2.8923 of 5 stars	$26.15 -2.6%	$41.00 +56.8%	+63.5%	$1.91B	$105.96M	N/A	264	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRD) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Opus Genetics (IRD) Competitors

IRD vs. MESO, STOK, BHVN, ZYME, and COAG

How does Opus Genetics compare to Mesoblast?

Summary

How does Opus Genetics compare to Stoke Therapeutics?

Summary

How does Opus Genetics compare to Biohaven?

Summary

How does Opus Genetics compare to Zymeworks?

Summary

How does Opus Genetics compare to Hemab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Opus Genetics (IRD) Competitors

IRD vs. MESO, STOK, BHVN, ZYME, and COAG

How does Opus Genetics compare to Mesoblast?

Is IRD or MESO more profitable?

Does the media prefer IRD or MESO?

Do analysts prefer IRD or MESO?

Which has more volatility and risk, IRD or MESO?

Which has preferable earnings and valuation, IRD or MESO?

Do insiders and institutionals hold more shares of IRD or MESO?

Summary

How does Opus Genetics compare to Stoke Therapeutics?

Do analysts rate STOK or IRD?

Which has more risk and volatility, STOK or IRD?

Does the media favor STOK or IRD?

Do institutionals & insiders hold more shares of STOK or IRD?

Is STOK or IRD more profitable?

Which has better earnings and valuation, STOK or IRD?

Summary

How does Opus Genetics compare to Biohaven?

Do analysts recommend IRD or BHVN?

Do institutionals and insiders hold more shares of IRD or BHVN?

Does the media favor IRD or BHVN?

Is IRD or BHVN more profitable?

Which has more risk & volatility, IRD or BHVN?

Which has preferable valuation and earnings, IRD or BHVN?

Summary

How does Opus Genetics compare to Zymeworks?

Is ZYME or IRD more profitable?

Do insiders and institutionals believe in ZYME or IRD?

Does the media prefer ZYME or IRD?

Do analysts prefer ZYME or IRD?

Which has better valuation and earnings, ZYME or IRD?

Which has more volatility and risk, ZYME or IRD?

Summary

How does Opus Genetics compare to Hemab Therapeutics?

Which has preferable earnings & valuation, COAG or IRD?

Does the media prefer COAG or IRD?

Is COAG or IRD more profitable?

Do analysts recommend COAG or IRD?

Do institutionals and insiders hold more shares of COAG or IRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRD vs. The Competition

Opus Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools